Income Statement
INHIBRX BIOSCIENCES, INC.
INBX
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY |
|---|---|---|
|
Revenue
|
1.30 | 0.20 |
|
Cost of Revenue
|
- | - |
|
Gross Profit
|
1.30 | 0.20 |
|
Operating Expenses
|
136.33 | 331.65 |
|
Research & Development
|
113.03 | 203.74 |
|
Selling, General & Administrative
|
23.30 | 127.91 |
|
Other Operating Expenses
|
- | - |
|
Operating Income
|
-135.03 | -331.45 |
|
Non-Operating Income
|
-5.03 | 2,019.02 |
|
Interest Income
|
- | - |
|
Interest Expense
|
12.20 | 13.50 |
|
Other Non-Op Income / Expense
|
-0.38 | 2,019.02 |
|
Income Before Tax
|
-140.05 | 1,687.57 |
|
Income Tax Expense
|
0.00 | 0.00 |
|
Non-Controlling Interest
|
- | - |
|
Net Income
|
-140.06 | 1,687.57 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY |
|---|---|---|
|
Depreciation & Amortization
|
- | - |
|
EBITDA
|
-132.54 | -329.16 |
|
Earnings Per Share (Basic)
|
-9.04 | 114.01 |
|
Diluted EPS
|
-9.04 | 112.62 |
|
Weighted Average Shares
|
15.49 | 14.80 |
|
Diluted Weighted Avg Shares
|
15.49 | 14.98 |
|
Comprehensive Income
|
- | - |